somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
=== Overlays === Significant structural weaknesses or damaged areas that do not support the textile such as bottom borders of tapestries or hems have different requirements. Borders or edges that are smaller can be wrapped to the back with a sheer overlay fabric to create a binding or facing. Partial or full backing secured with stitching is appropriate in other areas. Protection of exposed floats of the stabilization stitching, may require full-sized secondary linings.
Radiocarbon dating has established that the shroud is medieval, and not from the time of Jesus. Independent radiocarbon dating tests were carried out in 1988 at the University of Oxford, the University of Arizona and the Swiss Federal Institute of Technology, following years of discussion to obtain permission from the Holy See. The tests were done on portions of a swatch taken from a corner of the shroud, and concluded with 95% confidence that the material dated to AD 1260–1390. The dating matches the first appearance of the shroud in church history. This dating is also slightly more recent than that estimated by the art historian W. S. A. Dale, who postulated on artistic grounds that the shroud is an 11th-century icon made for use in worship services. Some proponents for the authenticity of the shroud have attempted to discount the radiocarbon dating result by claiming that the sample may represent a medieval "invisible mending" repair fragment rather than the image-bearing cloth. However, all of the hypotheses used to challenge the radiocarbon dating have been scientifically refuted, including the medieval repair hypothesis, the bio-contamination hypothesis and the carbon monoxide hypothesis. In recent years, the radiocarbon dating data have been repeatedly statistically analysed in attempts to draw some conclusions about the reliability of the radiocarbon dating from studying the data rather than studying the shroud itself.
== Ecology == Ginkgo biloba is the only vascular plant known to host a microalga, a Cocomyxa-like green alga, as an endosymbiont. This symbiosis is vertically inherited and present worldwide. The endosymbiont has been found in ginkgos in Asia, North America, and Europe. Photosynthetic activity does not occur as the algae are hosted intracellularly in an immature "precursor" form without a functional chloroplast. The endosymbiotic algae may be involved in metabolic pathways of the ginkgo host.
Small bowel/intestinal dialysis puts the dialysate in the small intestines through a surgical opening (ileostomy), using the intestinal walls as the semipermeable membrane for removing toxins. It did not show any actual survival benefit overall and was replaced by modern dialysis methods. Induced diarrhea has been found to provide toxin removal in small, non-randomly controlled studies. One method uses the ingestion of 1 to 1.5 liters of non-absorbable solutions of polyethylene glycol or mannitol every fourth hour. Colonic dialysis puts the dialysate in the colon, which can be done without a surgical opening: an anal catheter inserted through the anus can reach the ascending colon and inject the dialysate there. The clinical use of colonic dialysis is still in its early stages (as of 2020), being studied mainly in Iran and China. Oral adsorbents are used in hope that they will absorb toxins as they pass through the gut. One of them, AST-120, has undergone two multinational randomized controlled trials in which it failed to show a benefit in slowing CKD progression. However, a post-hoc analysis finds some benefit in a subgroup of patients. A related development is supplementation with soluble fibres such as acacia fibre into the diet. These fibers are digested by bacteria in the colon. This bacterial growth increases the amount of nitrogen that is eliminated in fecal waste.
Sources: en.wikipedia.org
In molecular biology, a selenoprotein is any protein that includes a selenocysteine (Sec, U, Se-Cys) amino acid residue. Among functionally characterized selenoproteins are five glutathione peroxidases (GPX) and three thioredoxin reductases, (TrxR/TXNRD) which both contain only one Sec. Selenoprotein P is the most common selenoprotein found in the plasma. It is unusual because in humans it contains 10 Sec residues, which are split into two domains, a longer N-terminal domain that contains 1 Sec, and a shorter C-terminal domain that contains 9 Sec. The longer N-terminal domain is likely an enzymatic domain, and the shorter C-terminal domain is likely a means of safely transporting the very reactive selenium atom throughout the body.
== Antiphage defense in Bacteria == Bacterial ubiquitination is an evolutionarily conserved protein modification pathway that plays a role in bacterial antiviral defense. It exhibits structural and functional parallels to eukaryotic ubiquitination systems and contributes to bacterial defense against Bacteriophage. Recent reviews highlight the conservation and similarity of bacterial and eukaryotic innate immunity mechanisms. In one study, it was demonstrated that during phage infection, a bacterial system conjugates a Ubl protein to the phage's central tail fiber, a component essential for tail assembly and host recognition. This modification leads to the production of defective phage particles with impaired infectivity, thereby protecting the bacterial population from phage proliferation. Another study revealed that a bacterial operon associated with phage defense encodes a complete ubiquitination pathway. Structural analyses of the bacterial E1–E2–Ubl complex showed significant similarities to canonical eukaryotic ubiquitination machinery, suggesting that the ubiquitination pathway may have originated in bacteria. In all organisms, innate immune pathways sense infection and rapidly activate potent immune responses while avoiding inappropriate activation (autoimmunity). In humans, the innate immune receptor cyclic GMP–AMP synthase (cGAS) detects viral infection to produce the nucleotide second messenger cyclic GMP–AMP (cGAMP), which initiates stimulator of interferon genes (STING)-dependent antiviral signaling.
population, Sanders stated that "we must end global oligarchy" and that "we need, in the United States and throughout the world, a tax system which is fair, progressive and transparent." On September 5, 2018, Sanders partnered with Ro Khanna to introduce the Stop Bad Employers by Zeroing Out Subsidies (Stop BEZOS) Act, which would require large corporations to pay for the food stamps and Medicaid benefits that their employees receive, relieving the burden on taxpayers.
=== Starting material === PMCA was originally based on the normal prion protein (PrPC) from healthy brain tissue, which is expensive. The advent of recombinant proteins have lower the cost somewhat, but the steps required to obtain the pure protein are laborious. In 2011, it was found that simply putting a prion protein transgene into a cell line and then lysing the cell without purification is enough. This is expected to make PMCA much cheaper. The cell line does not need to be of a neuronal origin. PMCA is most easily performed with catalysts which are abundant even in healthy cells: a polyanion (single-stranded RNA or sulfated glycans) and a phospholipid. A cell lysate would provide both of these catalysts and most clumps of PrPSc contain catalyst polyanion molecules anyways. Synthetic versions of these catalysts such as poly(A) RNA and 1-palmitoyl-2-oleoylphosphatidylglycerol (POPG) also work for propagating PrPSc. Additional required materials include buffer salts and detergent.
=== Non-biologic surface interaction === Non-biologic surface coatings will occur via two mechanisms, the first being direct hydrophobic interaction of the lipid tail with a hydrophobic surface resulting in a monolayer of FSL at the surface. The second surface coating will be through the formation of bilayers, which probably either encapsulate fibres or being via the hydrophilic F group. This is the expected mechanism by which FSLs bind to fibrous membranes such as paper and glass fibres. A recent study has found that when FSL Kode constructs are optimised, could in a few seconds glycosylate almost any non-biological surface including metals, glass, plastics, rubbers, and other polymers.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.